Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
View graph of relations


- Design of clinical trials according to Good Clinical Practice

- Work in lab: Cell culturing, flowcytometry

- Especially knowledge in malignant melanoma

Main research areas

Oncology: In more detail cancer immunotherapy: The use of a persons immune system to fight cancer; i.e. with monoclonal antibodies, cancer vaccines and T cell therapy. My main research area is to test safety, toxicity an clinical efficacy of peptide vaccines consisting of PD-L1 and IDO peptides in combination with the standard treatment Nivolumab (PD-1 blocking antibody) (first in patient with malignant melanoma, and hopefully expand to other cancer types).

Current research

Clinical trial with the title: "Combination therapy with Nivolumab and PD-L1/IDO peptide vaccine to patients with metastatic melanoma. Inclusion of the first patient in March 2017.

Potential conflicts of interest

No conflicts of interest

ID: 45659854